Clinical Trial Update: Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating an APA program's impact on event-free survival in first-line diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Snippet

Sponsor: Weprom | Conditions: Diffuse Large B Cell Lymphoma | Phase 3 | Status: RECRUITING